Monthly Archives: January 2018

Precision Vaccination highlighted our cancer vaccine, TPIV200 for treating triple-negative breast cancer.

Peter Hoang, President and CEO of TapImmune, is enthusiastic about a cancer vaccine under development by TapImmune that could help prevent recurrence of such cancers in women.

With new innovations and breakthroughs in the field of immunotherapy TapImmune CEO & President, Peter Hoang has been amazed by the change of pace within the field.

TapImmune President & CEO, Peter Hoang, to present at Biotech Showcase next week.